2025-04-22 - Analysis Report
## Colgate-Palmolive Co (CL) Stock Review

**0) Introduction:** This report analyzes Colgate-Palmolive Co (CL), a leading global consumer products company specializing in oral hygiene, personal care, and home care products.  The analysis incorporates cumulative return, recent price movements, technical indicators, earnings data, and financial information to assess the stock's performance and potential.


**1) Performance Comparison & Alpha/Beta Analysis:**

Colgate-Palmolive's cumulative return of 40.78% significantly lags behind the S&P 500's (VOO) return of 72.42%.  The difference is -31.6%, placing it at the 47.1st percentile of its historical range (-66.7% to 7.8%).

The provided Alpha/Beta analysis shows mixed results:

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 16.0% | 4.2% | -16.0% | 0.1 | 51.7 |
| 2016-2018  | -9.0% | 65.3% | -30.0% | 0.1 | 41.8 |
| 2017-2019  | 10.0% | 65.3% | -24.0% | -0.3 | 49.5 |
| 2018-2020  | 22.0% | 65.3% | -8.0% | 0.3 | 63.0 |
| 2019-2021  | 34.0% | 58.5% | -26.0% | 0.8 | 64.3 |
| 2020-2022  | 11.0% | 68.9% | 2.0% | 0.7 | 60.8 |
| 2021-2023  | 8.0% | 68.9% | -13.0% | 0.6 | 63.1 |
| 2022-2024  | 16.0% | 68.9% | -5.0% | 0.5 | 73.5 |
| 2023-2025  | 18.0% | 62.4% | 7.0% | 0.3 | 77.5 |

While CAGR (Compound Annual Growth Rate) shows periods of strong growth,  the negative Alphas in several periods suggest underperformance compared to the market benchmark. The beta generally indicates lower volatility than the market (below 1).


**2) Recent Price Movements:**

* **Closing Price:** $94.70
* **Previous Close:** $95.50
* **Change:** -$0.80 (a slight decrease)
* **5-day Moving Average:** $94.27
* **20-day Moving Average:** $92.24
* **60-day Moving Average:** $90.20

The price is slightly below the 5-day moving average, suggesting minor short-term downward pressure.  However, it remains above both the 20-day and 60-day moving averages, indicating a longer-term upward trend.


**3) Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.4082 (Medium Risk)
* **RSI:** 53.54 (slightly above neutral; not overbought)
* **PPO:** 0.3382 (positive, suggesting bullish momentum)
* **Relative Strength Divergence:** +9.7 (short-term upward momentum)
* **Expected Return:** -42.2% (This is a very negative figure and needs clarification.  It’s unclear how this was calculated. More detail is needed to interpret this reliably.)

The slight price drop indicated in `Last-market` is not a significant event (not a sharp drop or rebound). The overall technical indicators suggest a relatively neutral to slightly bullish outlook. The highly negative expected return warrants further investigation into its calculation methodology.


**4) Recent Earnings Analysis:**

| 날짜       | EPS  | 매출         |
|------------|------|---------------|
| 2024-10-25 | 0.9  | 5.03 B$       |
| 2024-07-26 | 0.89 | 5.06 B$       |
| 2024-04-26 | 0.83 | 5.07 B$       |
| 2023-10-27 | 0.86 | 4.92 B$       |
| 2024-10-25 | 0.86 | 4.92 B$       | *(Duplicate entry, likely an error)*


Revenue is relatively stable, hovering around $5 billion. EPS shows minor fluctuations but generally remains consistent.  The duplicate entry needs correction for accurate analysis.


**5) Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $4.95B | 60.30% |
| 2024-09-30 | $5.03B | 61.08% |
| 2024-06-30 | $5.06B | 60.62% |
| 2024-03-31 | $5.07B | 60.00% |
| 2023-12-31 | $4.95B | 59.60% |

Revenue remains consistent. Profit margins are high and stable, indicating strong profitability.

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-12-31 | $0.21B | 348.58% |
| 2024-09-30 | $0.43B | 169.43% |
| 2024-06-30 | $0.12B | 594.31% |
| 2024-03-31 | $0.23B | 296.96% |
| 2023-12-31 | $0.61B | 117.90% |

ROE (Return on Equity) is highly volatile and shows exceptionally high values in some quarters. This requires further investigation to understand the underlying causes and ensure data accuracy.  The significant fluctuations in equity are also concerning.


**6) Overall Conclusion:**

Colgate-Palmolive shows consistent revenue and high profit margins, indicating a financially healthy company.  However, the stock's underperformance relative to the S&P 500, along with the volatile ROE and the unexplained -42.2% expected return, raise significant concerns.  The relatively stable price action suggests a period of consolidation.  Further investigation into the data inconsistencies (duplicate earnings entry, highly volatile ROE) and clarification on the expected return calculation are crucial before forming a definitive investment opinion.  A thorough analysis of the company's competitive landscape and future growth prospects is also necessary.  The current data suggests a neutral outlook, but caution is advised due to the inconsistencies and the significant underperformance relative to the market benchmark.
